284
Participants
Start Date
September 11, 2018
Primary Completion Date
August 26, 2019
Study Completion Date
May 5, 2020
ofatumumab with PRF
ofatumumab 20 mg subcutanious injection administered with pre-filled syringe (PRF)
ofatumumab with AI
ofatumumab 20 mg subcutaneous injection administered with autoinjector (AI)
Novartis Investigative Site, Vienna
Novartis Investigative Site, Vienna
Novartis Investigative Site, Sofia
Novartis Investigative Site, Sofia
Novartis Investigative Site, Sofia
Novartis Investigative Site, Sofia
Novartis Investigative Site, Tallinn
Novartis Investigative Site, Pozuelo de Alarcón
Novartis Investigative Site, El Palmar
Novartis Investigative Site, Miami
Novartis Investigative Site, West Palm Beach
Novartis Investigative Site, Tampa
Novartis Investigative Site, Tampa
Novartis Investigative Site, Knoxville
Novartis Investigative Site, Castilleja de la Cuesta
Novartis Investigative Site, Indianapolis
Novartis Investigative Site, Tartu
Novartis Investigative Site, Ozark
Novartis Investigative Site, Sherman
Novartis Investigative Site, Round Rock
Novartis Investigative Site, Aurora
Novartis Investigative Site, Boulder
Novartis Investigative Site, Basalt
Novartis Investigative Site, Fullerton
Novartis Investigative Site, Moscow
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Kazan'
Novartis Investigative Site, Novosibirsk
Novartis Investigative Site, Krasnoyarsk
Novartis Investigative Site, Brno
Novartis Investigative Site, Havířov
Novartis Investigative Site, Teplice
Novartis Investigative Site, Hradec Králové
Novartis Investigative Site, Pardubice
Novartis Investigative Site, Riga
Novartis Investigative Site, Riga
Novartis Investigative Site, Riga
Novartis Investigative Site, Kaunas
Novartis Investigative Site, Vilnius
Novartis Investigative Site, Barcelona
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY